Work

Unraveling cancer metabolism through flux analysis and metabolic engineering

Year: 2015
Type: dissertation
Abstract: Cancer therapies have significantly improved over the last decades. However, some cancers, such as lung cancer, still have very poor outcomes and high mortality rates, even when proper treatment is applied. New treatment strategies must be adopted, which will require better understanding of cancer mechanisms. For that purpose, three human lung cell lines were used in this study, MRC-5, a human lung fibroblast cell line and A549, H1299, two human non-small lung cancer cells. The metabolic remodeling occurring in carcinogenesis cells is firmly established. However, to understand the connection between the cellular metabolic profile and carcinogenesis, an accurate measurement of metabolic fluxes is required. In order to quantify the fluxes in these metabolic pathways, stable isotopes tracers and nuclear magnetic resonance techniques were employed. For the quantification of carbon intermediary metabolism cells were grown in 13C labelled glucose while for de novo lipogenesis (DNL) assessment 2H2O was supplemented to the culture media. To better understand and characterize cellular bioenergetics, mitochondrial membrane potential, oxygen consumption, and energy charge were also assessed. Also, recent reports describe a reductive carboxylation operated by isocitrate dehydrogenase (IDH), which may provide acetyl-coenzyme A to DNL, favoring carcinogenesis. To evaluate the impact of this reaction in the overall metabolism, IDH isoforms 1 and 2 were genetically silenced and metabolism was assessed by stable isotopes tracers. Finally, to establish a bridge between metabolic fluxes and cancer proliferation, substrate dependency studies were performed. Several metabolic inhibitors were also tested, targeting glycolysis, TCA cycle, pentose phosphate pathway (PPP) and transaminases. In this work we were able to quantify the glycolytic, TCA cycle and DNL fluxes. All cell lines exhibited heterogeneous metabolic profiles, with two distinct cancer cell lines. A549 cell line exhibited a more glycolytic phenotype while the H1299 cell line showed relatively active TCA cycle. However, both cell lines exhibited an increased DNL rate relatively to MRC-5 cell line. The overall mitochondrial bioenergetic parameters were in agreement with the metabolic profiles. The mitochondrial network was polarized and active in all cell lines, although H1299 cell line exhibited higher basal oxygen consumption and spare respiratory capacity. The reductive carboxylation operated by IDH did not contributed significantly to DNL. However, IDH silencing altered the redox homeostasis and IDH1 silencing in the A549 cell line increased the 13C enrichment of glutamine pools. Relatively to substrate dependency, all cell lines exhibited a reduced proliferation under glutamine deprivation. Finally, metabolic inhibition studies revealed an increased sensitivity in cancer cell lines to the inhibition of glucose-6-phosphate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase and transaminases, all reactions able to supply anabolic precursors or reducing equivalents. This work revealed that A549 and H1299 cancer cell lines exhibited different metabolic profiles even though they are both derived from non-small lung cancer. Both cancer cell lines have increased DNL but the reductive carboxylation by IDH did not contributed significantly. Nevertheless, IDH is involved in redox homeostasis and IDH1 may have a regulatory effect on glutamine pools. We were able to establish a connection between the metabolic profile and potential therapeutic targets, such as DNL or PPP.
Language: English
Subfield: Cancer Research
Open Access status: green
OpenAlex ID: W2398422533
Cites: 281
Cited by:
Related to: 10